Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder arising from neoplastic transformation of hematopoietic stem/progenitor cells 1 by the p210 BCR/ABL protein that is translated from bcr/abl transcripts generated by the bcr/abl chimeric gene of the Philadelphia chromosome. [2] [3] [4] [5] The oncogenic potential of p210 BCR/ABL depends on its tyrosine kinase activity and rests on its ability to interact with and phosphorylate several substrates, which in turn activate cytoplasmic and nuclear effectors. 6 Numerous studies on the mechanisms of p210 BCR/ABL leukemogenesis have focused on the activation of cytoplasmic effectors such as RAS and PI-3K, 7,8 but less is known about the nuclear effectors, the mechanisms of their activation or loss of function, and their contribution to the phenotype of transformed cells. The nuclear effectors of p210 BCR/ABL include transcription factors whose activity is also modulated by the products of other leukemia-specific translocation or directly by mutation. 6 One of the transcription factors whose expression in enhanced by p210 BCR/ABL and may have an important role in BCR/ABLdependent leukemogenesis is c-Myb. 9 The importance of c-Myb in normal hematopoiesis is supported by studies showing that ablation of c-Myb expression leads to impaired liver hematopoiesis, 10 reduced erythroid and myeloid colony formation, 11 and defective B-and T-cell lymphopoiesis. 12, 13 The function of c-Myb may depend on its ability to modulate levels of genes (ie, CD34, c-Kit, Flt3) expressed by early progenitor cells and involved in the regulation of cell proliferation and survival. [14] [15] [16] A target of c-Myb in hematopoietic cells is also In CML cells, the c-Myb gene is intact 18,19 but expression is often increased, in part, via enhanced protein stability regulated by the PI-3K/Akt pathway 9 The c-Myb gene has been proposed as a therapeutic target in acute myelogenous leukemia (AML) and in CML based on the differential requirement of c-Myb by normal and leukemic cells. 20, 21 However, these studies were based on the use of antisense oligodeoxynucleotides in dose-response comparisons of normal and leukemic colony formation and on clonogenic assays of mixed normal and leukemic cells in which the phenotype of surviving cells was assessed by measuring bcr/abl transcripts. Since a genetic approach for assessing the role of c-Myb in BCR/ABL-dependent leukemogenesis has not been taken, we used hematopoietic progenitor cells from c-Myb knockout mice with 1 or 2 functional alleles to assess their reliance on c-Myb levels for p210 BCR/ABL -dependent in vitro transformation and leukemogenesis. We show here that p210 BCR/ABL -transduced Lin Ϫ Sca-1 ϩ and Lin Ϫ Sca-1 ϩ Kit ϩ marrow progenitors are more dependent than their normal counterpart on optimal c-Myb levels for primary and secondary colony formation. Moreover, in a mouse model of CML-blast crisis, p210 BCR/ABLexpressing wild-type c-Myb marrow cells induced primary and secondary leukemia with a shorter latency of that induced by c-Myb ϩ/Ϫ marrow cells.
Introduction
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder arising from neoplastic transformation of hematopoietic stem/progenitor cells 1 by the p210 BCR/ABL protein that is translated from bcr/abl transcripts generated by the bcr/abl chimeric gene of the Philadelphia chromosome. [2] [3] [4] [5] The oncogenic potential of p210 BCR/ABL depends on its tyrosine kinase activity and rests on its ability to interact with and phosphorylate several substrates, which in turn activate cytoplasmic and nuclear effectors. 6 Numerous studies on the mechanisms of p210 BCR/ABL leukemogenesis have focused on the activation of cytoplasmic effectors such as RAS and PI-3K, 7, 8 but less is known about the nuclear effectors, the mechanisms of their activation or loss of function, and their contribution to the phenotype of transformed cells. The nuclear effectors of p210 BCR/ABL include transcription factors whose activity is also modulated by the products of other leukemia-specific translocation or directly by mutation. 6 One of the transcription factors whose expression in enhanced by p210 BCR/ABL and may have an important role in BCR/ABLdependent leukemogenesis is c-Myb. 9 The importance of c-Myb in normal hematopoiesis is supported by studies showing that ablation of c-Myb expression leads to impaired liver hematopoiesis, 10 reduced erythroid and myeloid colony formation, 11 and defective B-and T-cell lymphopoiesis. 12, 13 The function of c-Myb may depend on its ability to modulate levels of genes (ie, CD34, c-Kit, Flt3) expressed by early progenitor cells and involved in the regulation of cell proliferation and survival. [14] [15] [16] A target of c-Myb in hematopoietic cells is also Bcl-2. 17 In CML cells, the c-Myb gene is intact 18, 19 but expression is often increased, in part, via enhanced protein stability regulated by the PI-3K/Akt pathway 9 The c-Myb gene has been proposed as a therapeutic target in acute myelogenous leukemia (AML) and in CML based on the differential requirement of c-Myb by normal and leukemic cells. 20, 21 However, these studies were based on the use of antisense oligodeoxynucleotides in dose-response comparisons of normal and leukemic colony formation and on clonogenic assays of mixed normal and leukemic cells in which the phenotype of surviving cells was assessed by measuring bcr/abl transcripts. Since a genetic approach for assessing the role of c-Myb in BCR/ABL-dependent leukemogenesis has not been taken, we used hematopoietic progenitor cells from c-Myb knockout mice with 1 or 2 functional alleles to assess their reliance on c-Myb levels for p210 BCR/ABL -dependent in vitro transformation and leukemogenesis. We show here that p210 BCR/ABL -transduced Lin Ϫ Sca-1 ϩ and Lin Ϫ Sca-1 ϩ Kit ϩ marrow progenitors are more dependent than their normal counterpart on optimal c-Myb levels for primary and secondary colony formation. Moreover, in a mouse model of CML-blast crisis, p210 BCR/ABLexpressing wild-type c-Myb marrow cells induced primary and secondary leukemia with a shorter latency of that induced by c-Myb ϩ/Ϫ marrow cells.
Levels of Bcl-2, but not c-Myc, were decreased in p210 BCR/ABLexpressing c-Myb ϩ/Ϫ marrow cells; however, ectopic Bcl-2 expression did not enhance colony formation of p210 BCR/ABL -transduced c-Myb ϩ/Ϫ Lin Ϫ Sca-1 ϩ Kit ϩ cells, suggesting that lower expression of several c-Myb-regulated genes may be involved in the reduced leukemogenic potential of these cells.
Methods
Mice c-Myb f/f and c-Myb f/d mice obtained from Dr Bender's laboratory were previously described. 11 p53 ϩ/Ϫ C57BL6/J mice were obtained from Taconic (Hudson, NY). Mice were genotyped according to published procedures. 12, 22 All experiments on mice were performed with approval of and in accordance with Thomas Jefferson University's Animal Care and Use Committee.
Culture conditions, isolation, and retroviral transductions of primary bone marrow progenitor cells
Murine bone marrow cells were obtained from the femurs of c-Myb f/f , c-Myb f/d , or p53 Ϫ/Ϫ c-Myb w/w or p53 Ϫ/Ϫ c-Myb w/d mice after hypotonic lysis and enrichment for lineage negative (Lin Ϫ ) hematopoietic precursors using the StemSep Mouse Progenitor Enrichment Kit protocol (StemCell Technologies, Vancouver, BC). For some experiments, Lin Ϫ cells were purified after lineage depletion of bone marrow cells using antibodies directed against CD3 (clone 145-2C11), CD45R/B220 (clone RA3-6B2), Ter-119, Ly6G and Ly-6C (Gr-1, clone RB6-8C5), and CD11b (Mac-1, clone M1/70) conjugated to a fluorochrome (BD Pharmingen, Franklin Lakes, NJ). Cells were then cultured for 24 hours in StemSpan SFEM medium (StemCell Technologies) supplemented with IL-3 (6 ng/mL), IL-6 (10 ng/ mL), and Kit ligand (KL, 50 ng/mL). Lin Ϫ Sca-1 ϩ and Lin Ϫ Sca-1 ϩ Kit ϩ cells were obtained by a MoFlo-MLS cell sorter (DAKO Cytomation, Carpinteria, CA) using PE-conjugated anti-Sca-1 (Ly-6A/E; clone E13-161.7) and APC-conjugated anti-c-Kit (CD117; clone 2B8) antibodies (BD Pharmingen). Cells were transduced with a retroviral stock of MigRI p210 BCR/ABL supernatant of transfected Phoenix cells in medium containing 50% (vol/vol) retroviral supernatant and 2 g/mL polybrene. Virus and cells were cosedimented at 684g for 45 minutes in a Sorvall RT-6000 centrifuge (Newton, CT) at 32°C. Retroviral medium was changed after a 3-to 4-hour adsorption and a second round of transduction and cosedimentation, and replaced with normal medium after 2 to 3 hours. A third round of transduction and cosedimentation was performed 24 hours later, and the retroviral medium was replaced with normal medium after a 5-hour adsorption. After 24 hours, cells were sorted for GFP expression and plated for colony-forming assays.
For ectopic expression of c-Myb or Bcl-2 in p210 BCR/ABL c-Myb f/d cells, transduced Lin Ϫ Sca-1 ϩ Kit ϩ cells p210 BCR/ABL were sorted for GFP expression by a MoFlo-MLS cell sorter (DAKO Cytomation) and cultured in StemSpan SFEM medium (StemCell Technologies) supplemented with IL-3 (6 ng/mL), IL-6 (10 ng/mL), and KL (50 ng/mL) for 3 days. Then, cells were transduced with a retroviral stocks of murine stem cell virus (MSCV)/puro or MSCV/puro/c-Myb (19) or MSCV/puro/Bcl-2 (43) whose viral titer was determined by assessing puromycin-resistant colonies of transduced 32Dcl3 myeloid precursor cells. Since the viral titer of the MSCV/puro retroviral stock yielded 5% to 10% fewer colonies than the MSCV/puro/c-Myb or MSCV/puro/Bcl-2 stock, the amount of retroviral stock used was adjusted to give equivalent viral titers. After 24 hours, cells (8 ϫ 10 4 /plate) were plated in methylcellulose cells in the presence of 1 g/mL puromycin. Colony formation was assessed 9 days later.
Colony formation assays
Clonogenic assays were carried out in Methocult H4230 (StemCell Technologies) in the presence of IL-3 (6 ng/mL), IL-6 (10 ng/mL), and Kit ligand (50 ng/mL) or 1/10th of the cytokines. Progenitor cells were plated in methylcellulose at different numbers (1 ϫ 10 3 to 5 ϫ 10 3 ) and colony formation was assessed after 7 days. Secondary colony formation was carried out using cells isolated from methylcellulose. After 3 washes with medium, cells were replated onto new plates and colonies counted after 7 days. Bone marrow cells were transduced with a retroviral stock of MigRIp-210 BCR/ABL supernatant by serial spininfection as described above and then injected into lethally irradiated (11Gy in 2 split doses of 5.5 Gy each) syngenic C57BL/6J mice by lateral tail-vein injection (10 6 cells/ mouse, 7% GFP ϩ cells). Mice showing signs of pain and suffering were killed and analyzed for the presence of leukemia. Diagnoses were established by pathologic and immunophenotypic analyses. Leukemic cells in bone marrow and spleen cells were subjected to immunophenotypic analyses for detection of the following markers: Gr-1, using a phycoerythrin (PE)-conjugated antimouse Ly-6G (Gr-1) antibody; Mac-1, using a phycoerythrin (PE)-conjugated antimouse CD11b (integrin ␣ M chain, Mac-1 chain); CD19, using a phycoerythrin (PE)-conjugated antimouse CD19 antibody; or Sca-1, using a phycoerythrin (PE)-conjugated antimouse Ly-6A/E (Sca-1) antibody. The antibodies were obtained from BD Pharmingen.
For secondary transplantation assays, leukemic cells were sorted for GFP positivity by a MoFlo-MLS cell sorter (DAKO Cytomation), and 24 hours later injected in sublethally (5Gy) irradiated syngenic C57BL/6J mice. Mice were killed when terminally ill.
Western blotting
Cells (6 ϫ 10 5 /30 L) were lysed in Laemmli buffer and heated to 100°C for 10 minutes, and lysates were used for Western blotting. Equal amounts of total cell lysate were loaded onto a 4% to 15% polyacrylamide gel (Ready Gel system; Bio-Rad Laboratories, Hercules, CA). Following electrophoresis, proteins were transferred to nitrocellulose (Whatman, Florham Park, NJ), using the mini Trans-Blot transfer apparatus for 1 hour at 100 V (Bio-Rad Laboratories). Nitrocellulose membranes were blocked by incubation in Tris (Tris-hydroxymethyl-aminomethane)-buffered saline (5 mM Tris, 135 mM NaCl, 5 mM KCl) containing 5% nonfat dry milk, 0.1% Tween 20 for 1 hour at room temperature followed by a 1-hour incubation with primary antibody diluted in blocking buffer. Proteins of interest were detected using anti-c-Myb monoclonal antibody (clone1.1; Upstate Biotechnology, Lake Placid, NY); anti-GRB2 monoclonal antibody (610112; BD Transduction Laboratories, Lexington, KY); PY20H anti-PTyr/ HRP monoclonal antibody (P11265; BD Transduction Laboratories); anti-c-Myc polyclonal antibody (N-262; Santa Cruz Biotechnology, Santa Cruz, CA); anti-Bcl-2 monoclonal antibody (7/Bcl-2; BD Transduction Laboratories); anti-cyclin B1 monoclonal antibody (GNS1, Santa Cruz Biotechnology), antiactin polyclonal antibody (Sigma-Aldrich, St Louis, MO); anti-B-Myb (N-19; Santa Cruz Biotechnology); and anti-c-Abl (Ab-3; Calbiochem, San Diego, CA); monoclonal antibodies. Filters were then washed extensively in Tris-buffered saline containing 5% nonfat dry milk, 0.1% Tween-20 before incubation for 30 minutes with either a donkey antirabbit horseradish peroxidase-conjugated or a sheep antimouse horseradish peroxidase-conjugated antibody, each diluted 1:10 000 in blocking buffer (GE Healthcare Little Chalfont, United Kingdom). Filters were then washed as described above and developed using an enhanced chemiluminescence substrate (Pierce, Rockford, IL).
Results

Loss of a c-Myb allele has modest effects on myeloid colony formation of bone marrow progenitors
c-Myb is predominantly expressed by primitive hematopoietic progenitor cells and its levels decrease during differentiation. 23 Moreover, c-Myb expression is elevated in many cases of acute myeloid and lymphoid leukemia, 24 but the mechanisms underlying such an increase are unclear except in a cohort of pediatric T-cell acute lymphoblastic leukemia (T-ALL). 25, 26 To test the requirement of c-Myb in normal hematopoiesis and p210 BCR/ABL leukemogenesis, we used heterozygous c-Myb knockout mice in which one allele has c-Myb exon 2 flanked by LoxP sites for eventual cleavage by the Cre recombinase, referred to here as the floxed Myb allele (Myb f ), and the second has been deleted (Myb d ). 12 To Figure 1C) , consistent with the observation that c-Kit is a c-Myb-regulated gene. 14 Hematopoietic reconstitution, tested 3 months after injecting 10 6 bone marrow cells from a c-Myb f/d or a c-Myb f/f mouse in 3 lethally irradiated syngenic mice, was also undistinguishable, based on peripheral blood and bone marrow cell counts (not shown) and the proportion of bone marrow cells expressing the Sca-1, c-Kit, Gr-1, and Mac-1 antigens (Figure 2) .
Since c-Myb is essential for myeloid bone marrow colony formation, we tested the clonogenic potential of the Lin Ϫ , Lin Ϫ Sca-1 ϩ , and the Lin Ϫ Sca-1 ϩ Kit ϩ progenitor subsets by methylcellulose colony formation assays. Enriched Lin Ϫ and Lin Ϫ Sca-1 ϩ cells from c-Myb f/d mice formed approximately 25% fewer colonies than the counterpart from c-Myb f/f mice ( Figure 3A,B) . Colony formation and c-Myb expression were also assessed using "purified Lin Since secondary colony formation reflects the self-renewal potential of transformed cells, we performed secondary colony formation assays using cells isolated from methylcellulose. After primary plating of GFP ϩ HSCs, cells recovered from methylcellulose were replated in the presence of an optimal cytokine concentration or with 1/10th of the cytokines. p210 BCR/ABL -transduced c-Myb f/f cells were 4-to 9-fold more clonogenic than c-Myb f/d cells in the presence of full dose of cytokines or 1/10th of the cytokines, respectively ( Figure 5 ). Taken together, these data indicate that primary and secondary colony formation of p210 BCR/ABLtransduced marrow progenitors is more efficient if both copies of the c-Myb gene are intact; moreover, by comparing colony assays of nontransduced and p210 BCR/ABL -expressing hematopoietic progenitors, the latter appear to depend on c-Myb expression more than the nontransduced counterpart ( Figure 3 ).
To further demonstrate that the reduced colony formation potential of p210 BCR/ABL -transduced c-Myb f/d marrow progenitors is caused by lower c-Myb levels, we attempted to restore colony Figure 3 . Loss of a c-Myb allele has modest effects on colony formation of bone marrow progenitors. Colony formation assays were performed using (A) enriched Lin Ϫ marrow cells (5 ϫ 10 3 cells/plate) plated in methylcellulose in the presence of GM-CSF (P ϭ .015); (B) Lin Ϫ Sca-1 ϩ marrow cells (5 ϫ 10 3 cells/plate) plated in methylcellulose in the presence of IL-3, IL-6, and KL (P ϭ .008); and (C) Lin Ϫ Sca-1 ϩ Kit ϩ marrow cells (2.5 ϫ 10 5 /plate) plated in methylcellulose in the presence of optimal (IL-3, 6 ng/mL; IL-6, 10 ng/mL; KL, 50 ng/mL) or suboptimal (1/10th) cytokine concentrations; P ϭ .011 and P Յ .001, respectively. Representative of 3 different experiments performed in duplicate. 
Expression of c-Myb-regulated genes in c-Myb f/f or Myb f/d p210 BCR/ABL -transduced progenitors
The reduced colony formation of transduced marrow progenitors may be caused by changes in the expression of c-Myb-regulated genes with a role in cell proliferation and survival.
One of the c-Myb targets implicated in these processes is c-myc. 27 c-Myc is expressed in almost all proliferating normal cells, and down-regulation of c-Myc expression is required for terminal differentiation of many cell types, including myeloid cells. [28] [29] [30] For Figure 7B ).
c-Myb is required for BCR/ABL-dependent leukemogenesis
Transplantation of lethally irradiated mice with p210 BCR/ABL -retrovirally transduced bone marrow cells from 5-FU-treated mice to obtain a target population enriched in primitive hematopoietic cells induces a myeloproliferative syndrome resembling human CML. Since c-Myb f/d mice are more radiosensitive than normal mice 33 and the recovery of HSCs and other progenitor subsets is lower from 5-FU-treated c-Myb f/d than c-Myb f/f mice (not shown), we assessed the role of c-Myb in p210 BCR/ABL -dependent leukemogenesis using an in vivo model of CML-blast crisis. 22 In this model, mice injected with p53-deficient, p210 BCR/ABL -expressing marrow cells develop a more aggressive disease process than those injected with wild-type p53, BCR/ABL-expressing marrow cells. 22 We Sixty-seven percent of mice (n ϭ 12) reconstituted with p210 BCR/ABL p53 Ϫ/Ϫ c-Myb w/d marrow cells developed leukemia and died between 39 and 134 days after injection with a median survival of 96 days, more than 3-fold longer than that of p210 BCR/ABL p53 Ϫ/Ϫ c-Myb w/w -reconstituted mice ( Figure 8B ). By immunophenotype, GFP ϩ cells were lymphoid (CD19 ϩ ) in 2 mice, and neither myeloid nor lymphoid in 1 mouse; the remaining mice had splenomegaly, but were not immunophenotyped because viable cells were not recovered from bone marrow or spleen.
The ability to serially transplant leukemic cells is a standard measure of their malignant potential. Sublethally irradiated (500 rad) recipient mice (n ϭ 3) were injected with 1.0 ϫ 10 5 GFP ϩ bone marrow cells from a leukemic p53 Ϫ/Ϫ c-Myb w/w mouse, which had a mixed-lineage leukemia (GFP ϩ Gr-1 ϩ , and GFP ϩ CD19 ϩ cells in bone marrow and spleen). The 3 injected mice developed a CD19 ϩ lymphoblastic leukemia and died within 28 days ( Figure 8C ). Sublethally irradiated recipient mice (n ϭ 3) were also injected with 1.0 ϫ 10 5 GFP ϩ bone marrow cells from a leukemic p53 Ϫ/Ϫ c-Myb w/d mouse. All GFP ϩ cells were Gr-1 Ϫ and CD19 Ϫ . Of the 3 injected mice, 2 developed leukemia with the GFP ϩ cells also expressing the IL-7R and died 62 and 84 days after transplantation, while 1 is still alive ( Figure 8C ). Thus, p210 BCR/ABLexpressing p53 Ϫ/Ϫ c-Myb w/d cells were less leukemogenic than p53 Ϫ/Ϫ c-Myb w/w cells also in secondary recipient mice. Together, these data suggest that c-Myb is important for induction and maintenance of p210 BCR/ABL -dependent leukemogenesis.
Discussion
Crucial roles for c-Myb during normal hematopoiesis have been established by a variety of strategies involving permanent and conditional inactivation of the c-Myb gene, 10,12,13,34 expression of chimeric proteins with dominant-negative activity, 35 and inhibition of gene expression by antisense oligodeoxynucleotides. 20, 21 Expression of c-Myb is often increased in acute leukemia blasts, but knowledge of the mechanisms underlying such an increase remains elusive. In a large cohort of CML-chronic phase and CML-blast crisis samples, we found no evidence of c-Myb mutations in the coding sequence or the exon/intron junctions, 19 and amplification or truncation of c-Myb has previously been revealed only in 2 acute leukemia cell lines. 36, 37 Duplication or translocation of the c-Myb gene has been recently demonstrated in a cohort of pediatric T-ALL patients, 25, 26 essentially providing the first evidence that c-Myb can be activated by genetic mechanisms in human hematologic malignancies. Despite the lack of satisfactory mechanisms explaining the enhanced expression of c-Myb in leukemia blast cells, down-regulation of c-Myb expression in leukemic cells by use of antisense oligodeoxynucleotides was associated with reduced colony formation in vitro 20, 21 and suppression of leukemogenesis in mice. 38 Of greater interest, leukemic blast cells appeared to rely on c-Myb expression more than normal progenitors, based on dose-response comparisons of normal and leukemic colony formation. 20 However, the significance of these findings has remained somehow limited in the absence of genetic models in which to test the requirement of c-Myb expression for transformation by specific oncogenic proteins. In the present study, we assessed the requirement of c-Myb for p210 BCR/ABLdependent colony formation and leukemogenesis, using bone marrow cells from c-Myb knockout mice with only a single functional c-Myb allele.
Using different progenitor subsets, c-Myb f/d marrow cells yielded only 20% to 28% fewer colonies than c-Myb f/f marrow cells. These findings are in agreement with those showing that fetal liver colony formation was affected only if c-Myb levels were very low. 39 Upon transduction with p210 BCR/ABL , c-Myb f/d progenitors were markedly less clonogenic (50%-80% fewer colonies), both in primary and secondary colony formation assays and when transduced cells were plated in the presence of suboptimal cytokine concentrations.
The reduced colony formation potential of p210 BCR/ABLtransduced c-Myb f/d HSCs was dependent on lower c-Myb levels because it increased dramatically after retroviral transduction with full-length c-Myb in experiments designed to restore c-Myb expression.
To test the requirement of c-Myb for p210 BCR/ABL -dependent leukemogenesis, we could not rely on transplantation of lethally irradiated recipient mice with p210 BCR/ABL -transduced bone marrow cells from 5-FU-treated mice: c-Myb heterozygous knockout are more radiosensitive than wild-type mice 33 and, after 5-FU treatment, fewer marrow cells were recovered and number and distribution of progenitors subsets was also altered. Thus, we used marrow cells from p53 Ϫ/Ϫ c-Myb w/w or p53 Ϫ/Ϫ c-Myb w/d mice because the p53 Ϫ/Ϫ background compensates the radiosensitivity of c-Myb w/d mice and the disease process induced by p210 BCR/ABL -transduced p53 Ϫ/Ϫ cells is rather aggressive, resembling CML-blast crisis. 22 In agreement with the results of the colony formation assays, loss of c-Myb allele adversely affected p210 BCR/ABL -dependent leukemogenesis as indicated by the longer survival of p53 Ϫ/Ϫ cMyb w/d mice.
Thus, using well-defined genetic models we have demonstrated that c-Myb is required for p210 BCR/ABL -dependent leukemogenesis and that p210 BCR/ABL -expressing progenitors rely on optimal levels of c-Myb more than the nontransduced counterpart.
